Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

451

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Esophagitis, RefluxEsophagitis, Peptic
Interventions
DRUG

Dexlansoprazole MR

Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.

DRUG

Dexlansoprazole MR

Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.

DRUG

Placebo

Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.

Trial Locations (100)

Unknown

Anniston

Hueytown

Huntsville

Tallassee

Tuscaloosa

Tucson

Little Rock

North Little Rock

Azusa

Carmichael

Cypress

Fresno

Los Angeles

Modesto

Newport Beach

Oakland

Orange

San Diego

Santa Maria

Littleton

Longmont

Wheat Ridge

Bristol

Newark

Fort Myers

Miami

Naples

New Smyrna Beach

Ocala

Pembroke Pines

Port Orange

Sarasota

St. Petersburg

Zephyrhills

Atlanta

Champaign

Moline

North Chicago

Oak Forest

Springfield

Evansville

Indianapolis

Newburgh

Davenport

Kansas City

Wichita

Lexington

Louisville

Baton Rouge

Chevy Chase

Prince Frederick

Jackson

Jefferson City

Kansas City

St Louis

Missoula

Egg Harbor

Albuquerque

Chapel Hill

Charlotte

Greensboro

High Point

Raleigh

Wilmington

Winston-Salem

Bismarck

Akron

Columbus

Dayton

Mogadore

Oklahoma City

Medford

Portland

Philadelphia

Warwick

Anderson

Mt. Pleasant

Sioux Falls

Chattanooga

Germantown

Jackson

Johnson City

Kingsport

Amarillo

Conroe

Dallas

Fort Worth

Houston

Odessa

Pharr

Seguin

Temple

Salt Lake City

Charlottesville

Norfolk

Richmond

Bellevue

Lakewood

Tacoma

Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY